AbbVie: Osteoporosis trials

The registry lists 13 Osteoporosis studies with AbbVie as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 3Phase 2 1Phase 3 5Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of Stopping Risedronate After Long Term Treatment on Bone TurnoverCompletedNCT01249261Phase 3Results posted
• Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid ArthritisCompletedNCT01078155Results posted
• Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal WomenCompletedNCT00918749Phase 2Results posted
• Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With OsteoporosisCompletedNCT00619957Phase 3Results posted
• Bone Microarchitecture in Osteopenic Postmenopausal WomenTerminatedNCT00577395Phase 4Results posted
• A Study of a 35 mg Delayed Release Formulation of Risedronate for OsteoporosisCompletedNCT00541658Phase 3Results posted
• A Study of Monthly Risedronate for OsteoporosisCompletedNCT00247273Phase 3Results posted
• A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female SubjectsCompletedNCT00846196Phase 1
• Analysis of Iliac Crest Biopsies From Patients Receiving RisedronateCompletedNCT00837746
• Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or RisedronateCompletedNCT00778154
• Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy SubjectsCompletedNCT00699777Phase 1
• Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral DoseCompletedNCT00577850Phase 1
• Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMOCompletedNCT00577421Phase 3